IRIS
GEBBIA, VITTORIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.226
NA - Nord America 2.164
EU - Europa 1.796
SA - Sud America 654
AF - Africa 43
OC - Oceania 1
Totale 6.884
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.090
IE - Irlanda 1.057
SG - Singapore 1.032
HK - Hong Kong 847
BR - Brasile 606
DE - Germania 165
IT - Italia 165
GB - Regno Unito 135
TR - Turchia 83
FR - Francia 62
CN - Cina 59
CA - Canada 40
FI - Finlandia 40
IN - India 39
BD - Bangladesh 38
CH - Svizzera 37
VN - Vietnam 28
MX - Messico 27
NL - Olanda 23
IQ - Iraq 21
AR - Argentina 18
RU - Federazione Russa 18
ZA - Sudafrica 17
AT - Austria 14
CZ - Repubblica Ceca 14
SE - Svezia 13
MA - Marocco 12
JP - Giappone 11
PL - Polonia 10
UA - Ucraina 10
UZ - Uzbekistan 8
ES - Italia 7
VE - Venezuela 7
KR - Corea 6
LT - Lituania 6
PK - Pakistan 6
PY - Paraguay 6
SA - Arabia Saudita 6
AL - Albania 5
BO - Bolivia 5
EC - Ecuador 5
IL - Israele 5
JO - Giordania 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
KZ - Kazakistan 4
LB - Libano 4
BE - Belgio 3
NP - Nepal 3
UY - Uruguay 3
BA - Bosnia-Erzegovina 2
CL - Cile 2
DZ - Algeria 2
IR - Iran 2
KE - Kenya 2
LV - Lettonia 2
OM - Oman 2
PH - Filippine 2
RO - Romania 2
SN - Senegal 2
AO - Angola 1
AU - Australia 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
CO - Colombia 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
GD - Grenada 1
GR - Grecia 1
HN - Honduras 1
ID - Indonesia 1
JM - Giamaica 1
KG - Kirghizistan 1
NO - Norvegia 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TM - Turkmenistan 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 6.884
Salva come PNG Salva come JPEG
Città #
Dublin 1.051
Hong Kong 844
Singapore 394
Boardman 376
Santa Clara 322
The Dalles 266
Dallas 237
Ashburn 115
London 97
Istanbul 69
Assago 56
Munich 54
São Paulo 49
Los Angeles 44
Zurich 37
Helsinki 36
Chicago 34
Prineville 26
Milan 25
Fort Worth 24
Frankfurt am Main 24
Chandler 23
Rio de Janeiro 23
Belo Horizonte 19
Brooklyn 18
Boston 17
Springfield 17
Amsterdam 15
Montreal 15
Naples 15
New York 14
San Francisco 14
Brasília 12
Johannesburg 12
Ottawa 12
Washington 12
Atlanta 11
Tokyo 11
Mexico City 10
Phoenix 10
Berlin 9
Brno 9
Catania 9
Curitiba 9
Baghdad 8
Charlotte 8
Dhaka 8
Düsseldorf 8
New Delhi 8
Porto Alegre 8
Seattle 8
Shanghai 8
Tashkent 8
Nuremberg 7
Warsaw 7
Campo Grande 6
Erbil 6
Goiânia 6
Guarulhos 6
Hanoi 6
Lauterbourg 6
Misilmeri 6
Rome 6
Stockholm 6
Amman 5
Caxias do Sul 5
Columbus 5
Ho Chi Minh City 5
Itaquaquecetuba 5
Juiz de Fora 5
Moscow 5
Olomouc 5
Philadelphia 5
Princeton 5
Seoul 5
Sorocaba 5
Vienna 5
Volta Redonda 5
Asunción 4
Baku 4
Bauru 4
Betim 4
Campinas 4
Chennai 4
Guangzhou 4
Guayaquil 4
Jeddah 4
Modena 4
Piracicaba 4
Portsmouth 4
Praia Grande 4
Recife 4
Roubaix 4
Santa Cruz 4
Tirana 4
Vila Velha 4
West Jordan 4
Ankara 3
Anápolis 3
Aparecida de Goiânia 3
Totale 4.791
Salva come PNG Salva come JPEG
Nome #
112. UN NUOVO INDICE PROGNOSTICO-TERAPEUTICO IN ONCOLOGIA GERIATRICA 251
Is G8 geriatric assessment tool useful in managing elderly patients with metastatic pancreatic carcinoma? 81
Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis 70
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 66
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 65
Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated? 61
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 59
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 58
Patients With Cancer and COVID-19: A WhatsApp Messenger-Based Survey of Patients' Queries, Needs, Fears, and Actions Taken 56
Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer 55
Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis 55
A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy 55
Harmful Interference of Detoxifying Diets and Nutraceuticals with Adherence to Abemaciclib in Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Case Report 54
Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: A whatsapp messenger-based report from the Italian college of chief medical oncologists 53
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 51
Gastric metastasis from breast cancer 49
A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer 49
Combined Neuroendocrine Carcinoma and Hepatocellular Carcinoma of the Liver: Systematic Literature Review Suggests Implementing Biological Characterization to Optimize Therapeutic Strategy 48
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients 45
[First line chemotherapy in non-small cell lung carcinoma: a solved dilemma] 42
Safety of a 3-weekly schedule of carboplatin pegylate liposomal doxorubicin as first line chemotherapy results in patients with ovarian cancer preliminary results of the MITO-2 randomized trial 41
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial. 40
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 40
Non-palpable Pulmonary Nodules and Uniportal-VATS: Radio-guided Localization (ROLL) Experience of a Lung Multidisciplinary Team 40
A review and metanalysis of metronomic oral single-agent cyclophosphamide for treating advanced ovarian carcinoma in the era of precision medicine 40
Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety 39
High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data 39
null 37
5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group 36
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial 36
Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice 35
Impressive objective response to nab-paclitaxel plus trastuzumab as fifth line therapy in aelderly her2-positive breast cancer patient 34
Brain Metastasis in Endometrial Cancer: A Systematic Review 33
A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study 33
5-fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma: a randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group 32
The Effects of the Macrocyclic Lactone Bryostatin-1 on Leukemic Cells in Vitro 32
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium 30
In vivo stimulation of murine haematopoiesis by the antineoplastic agent bryostatin-1 30
A Phase I—II Study of Cyclophosphamide, Epidoxorubicin, Levofolinic Acid/5-Fluorouracil and Recombinant Human Granulocyte Colony Stimulating Factor in Metastatic Breast Carcinoma 30
New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful? 30
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial 30
Toward a New Prognostic-Therapeutic Index in Geriatric Oncology 30
First-line treatment with epirubicin and vinorelbine in metastatic breast cancer 29
Relationship of Inflammatory Parameters and Nutritional Status in Cancer Patients 29
null 29
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial 29
Hemolytic uremic syndrome after chemotherapy with gemcitabine and taxotere: A case report 29
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial 28
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA) 28
Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale 28
Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo-leucovorin in untreated patients with advanced colorectal carcinoma 28
null 28
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin plus etoposide in extensive small-cell lung cancer (SCLC) patients The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial 28
Nutritional management of the patient with pancreatic cancer: From the diagnostic and therapeutic pathway to an integrated hospital-territory approach 27
Cancer: New needs, new models. is it time for a community oncologist? another brick in the wall 27
Combination Chemotherapy with Cyclophosphamide, Doxorubicin and Vincristine in the Treatment of Stage III-IV Small-Cell Lung Cancer 27
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study 27
Radiofrequency Thermoablation and Hypofractionated Radiotherapy Combined Treatment for Bone Metastases: A Retrospective Study 27
The impact of anemia on quality of life and hospitalisation in elderly cancer patients undergoing chemotherapy 27
Cisplatin and vinorelbine in advanced and/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimen 27
The in vitro effect of the antineoplastic agent bryostatin 4 on human hematopoietic progenitor cells 27
null 27
Chemotherapy in Head and Neck Cancer (I): Management of Recurrent or Metastatic Disease 26
Escalating doses of mitoxantrone with granulocyte colony-stimulating factor (G-CSF) rescue plus 5-fluorouracil and high-dose levofolinic acid in metastatic breast cancer 26
Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial 26
Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society of Medical Oncology (AIOM) 26
New opioids. 26
Abemaciclib in Patients with End-Stage Renal Disease and Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Report of 2 Cases 26
Soluble interleukin-2 receptor in vitro production by mononuclear cells from Hodgkin patients 26
A Phase II Study of Levofolinic Acid and 5-Fluorouracil Plus Cisplatin in Patients with Advanced Head and Neck Squamous Cell Carcinoma 26
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations 26
5-Fluorouracil and Recombinant Alpha Interferon-2a in the Treatment of Advanced Colorectal Carcinoma: a Dose Optimization Study 26
A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer 26
null 26
Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience 25
Harmful Interference of Detoxifying Diets and Nutraceuticals with Adherence to Abemaciclib in Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Case Report 25
A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma 25
A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer. 25
Neo-adjuvant organ-preserving chemotherapy in the management of locally advanced oral cavity and oropharynx cancer 25
Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study 25
Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy Oncology Group 25
5-fluorouracil plus folinic acid with or without ifosfamide in advanced colorectal cancer: a phase II randomized trial 25
TOWARD A NEW PROGNOSTIC-THERAPEUTIC INDEX IN GERIATRIC ONCOLOGY 25
Liability of clinical oncologists and the COVID-19 emergency: Between hopes and concerns 25
Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE) 24
Vinblastine and Interferon-Alpha-2a Regimen in the Treatment of Metastatic Renal Cell Carcinoma 24
Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas 24
Alpha interferon in the treatment of hairy cell leukemia 24
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study 24
Subcutaneous recombinant-human-erythropoietin prevents chemotherapy-related anemia in patients with advanced cancer 24
Cetuximab in squamous cell head and neck carcinomas 24
A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group 24
Virtual clinical and precision medicine tumor boards-cloud-based platform-mediated implementation of multidisciplinary reviews among oncology centers in the covid-19 era: Protocol for an observational study 23
Evolution of Therapy Decision-Making Process for Advanced Non-Small Cell Lung Cancer 23
The multipotential hematopoietic growth factors, bryostatins, inhibit human leukemia cell lines in vitro 23
The Consistency and Quality of ChatGPT Responses Compared to Clinical Guidelines for Ovarian Cancer: A Delphi Approach 23
Non-palpable Pulmonary Nodules and Uniportal-VATS: Radio-guided Localization (ROLL) Experience of a Lung Multidisciplinary Team 23
5-fluorouracil plus high dose levofolinic acid and oral hydroxyurea for the treatment of primary hepatocellular carcinomas: Results of a phase II multicenter study of the Southern Italy Oncology Group (G.O.I.M.) 23
Correlation between sentinel lymph node biopsy and non-sentinel lymph node metastasis in patients with cN0 breast carcinoma: comparison of invasive ductal carcinoma and invasive lobular carcinoma 23
Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells 23
Totale 3.584
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.070
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.070
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202226 0 0 0 0 0 0 0 5 2 7 2 10
2022/2023174 13 14 4 8 6 13 3 12 8 3 49 41
2023/2024970 39 84 66 77 138 104 158 62 50 52 40 100
2024/20255.303 423 366 528 100 512 470 409 278 757 561 565 334
2025/2026756 642 114 0 0 0 0 0 0 0 0 0 0
Totale 7.229